314 related articles for article (PubMed ID: 19418217)
1. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
4. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
9. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
[TBL] [Abstract][Full Text] [Related]
12. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Lai YL; Mau BL; Cheng WH; Chen HM; Chiu HH; Tzen CY
Ann Surg Oncol; 2008 Apr; 15(4):1064-9. PubMed ID: 18183466
[TBL] [Abstract][Full Text] [Related]
14. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
16. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF
Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations in breast cancer are associated with poor outcome.
Li SY; Rong M; Grieu F; Iacopetta B
Breast Cancer Res Treat; 2006 Mar; 96(1):91-5. PubMed ID: 16317585
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
19. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Lee JW; Soung YH; Kim SY; Lee HW; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Oncogene; 2005 Feb; 24(8):1477-80. PubMed ID: 15608678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
